Mary Schapiro - CVS Health Independent Director
| CVS Stock | USD 59.85 0.11 0.18% |
Director
Ms. Mary L. Schapiro is Independent Director of the Company. Since January 2014, Ms. Schapiro has served as the Vice Chair of Promontory Advisory Board, part of Promontory Financial Group, a leading strategy, risk management and regulatory compliance firm that was acquired by IBM Corporation in November 2016. She previously served as managing director of Promontory Financial Group from March 2013 through January 2014. From January 2009 through December 2012, Ms. Schapiro was Chairman of the U.S. Securities and Exchange Commission, becoming the first woman to serve as that agencys Chairman. Prior to becoming SEC Chairman, Ms. Schapiro was Chairman and CEO of the Financial Industry Regulatory Authority from 2006 through 2008, and prior to that held a number of key executive positions at FINRA and its predecessor from 1996 through 2006, including Vice Chairman and President of NASD Regulation. She also served as Chairman of the Commodity Futures Trading Commission from 1994 to 1996, and was the only person to serve as Chairman of both the CFTC and the SEC. Ms. Schapiro is also a director of The London Stock Exchange Group plc, which engages in market infrastructure and the capital markets business since 2017.
| Age | 65 |
| Tenure | 7 years |
| Address | One CVS Drive, Woonsocket, RI, United States, 02895 |
| Phone | 401 765 1500 |
| Web | https://www.cvshealth.com |
CVS Health Management Efficiency
The company has Return on Asset of 0.0237 % which means that on every $100 spent on assets, it made $0.0237 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.067 %, implying that it generated $0.067 on every 100 dollars invested. CVS Health's management efficiency ratios could be used to measure how well CVS Health manages its routine affairs as well as how well it operates its assets and liabilities. At this time, CVS Health's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.06 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, CVS Health's Intangibles To Total Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.33 in 2024, whereas Other Assets are likely to drop slightly above 4.8 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James OBrien | Humana Inc | 66 | |
| Orlando Ayala | Centene Corp | 64 | |
| Daniel Cooperman | Molina Healthcare | 70 | |
| Eric Foss | Cigna Corp | 62 | |
| Roman Martinez | Cigna Corp | 71 | |
| John Partridge | Cigna Corp | 71 | |
| William Ballard | UnitedHealth Group Incorporated | 77 | |
| Mark McClellan | Cigna Corp | 57 | |
| David Jones | Humana Inc | 71 | |
| Frank Bisignano | Humana Inc | 62 | |
| Glenn Renwick | UnitedHealth Group Incorporated | 64 | |
| John Noseworthy | UnitedHealth Group Incorporated | 69 | |
| Dale Wolf | Molina Healthcare | 66 | |
| Richard Gephardt | Centene Corp | 79 | |
| Kimberly Ross | Cigna Corp | 56 | |
| Eric Wiseman | Cigna Corp | 65 | |
| Frank DAmelio | Humana Inc | 63 | |
| William McDonald | Humana Inc | 64 | |
| John Roberts | Centene Corp | 78 | |
| Jessica Blume | Centene Corp | 66 | |
| Robert Ditmore | Centene Corp | 86 | |
Management Performance
| Return On Equity | 0.067 | ||||
| Return On Asset | 0.0237 |
CVS Health Corp Leadership Team
Elected by the shareholders, the CVS Health's board of directors comprises two types of representatives: CVS Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CVS. The board's role is to monitor CVS Health's management team and ensure that shareholders' interests are well served. CVS Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CVS Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Independent Director | ||
| Sreekanth MD, Executive Officer | ||
| David Dorman, Independent Chairman of the Board | ||
| Shawn Guertin, Chief Financial Officer, Executive Vice President | ||
| Mary Schapiro, Independent Director | ||
| FACEP MD, VP Officer | ||
| Fernando Aguirre, Independent Director | ||
| Laurence McGrath, Senior Relations | ||
| Laurie Havanec, Chief People Officer, Executive Vice President | ||
| Norman Greve, Chief Officer | ||
| C Brown, Independent Director | ||
| NancyAnn DeParle, Independent Director | ||
| David CEBS, Executive Caremark | ||
| Tilak Mandadi, Data, Digital | ||
| Thomas Cowhey, Executive CFO | ||
| JeanPierre Millon, Independent Director | ||
| Alecia DeCoudreaux, Independent Director | ||
| William Weldon, Independent Director | ||
| Larry McGrath, Sr Relations | ||
| Samrat Esq, Chief VP | ||
| Joshua Flum, Executive Vice President, Chief Strategy and Business Development Officer | ||
| Heidi Capozzi, Executive Officer | ||
| Troyen Brennan, Executive Vice President Chief Medical Officer | ||
| Prem Shah, Executive Vice President, Chief Pharmacy Officer and Co-President of Retail | ||
| Lisa Bisaccia, Chief Human Resource Officer, Executive Vice President | ||
| Karen Lynch, President, Chief Executive Officer, Director | ||
| Thomas Moriarty, Executive Vice President, General Counsel, Chief Policy and External Affairs Officer | ||
| Katerina Guerraz, Chief VP | ||
| Tony White, Independent Director | ||
| Anne Finucane, Independent Director | ||
| Vijay Patel, Senior CoFounder | ||
| James Clark, Senior Vice President - Controller, Chief Accounting Officer | ||
| Eva Boratto, Chief Financial Officer, Executive Vice President | ||
| David Falkowski, Executive Officer | ||
| Prem PharmD, Group President | ||
| Jonathan Roberts, Chief Operating Officer, Executive Vice President | ||
| Gustavo Giraldo, Head Benefits | ||
| Daniel Finke, Executive Vice President and Presidentident - Health Care Benefits Segment | ||
| Larry Merlo, President, Chief Executive Officer, Director | ||
| Alan Lotvin, Executive Vice President and Presidentident - CVS Caremark | ||
| Neela Montgomery, Executive Vice President and President - CVS Pharmacy/Retail | ||
| Alan MD, Ex Services | ||
| Roger Farah, Independent Director | ||
| Sheryl Burke, Chief Responsibility | ||
| MPP MD, Senior President | ||
| Michelle Peluso, Executive Vice President, Chief Customer Officer and Co-President of Retail |
CVS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CVS Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.067 | ||||
| Return On Asset | 0.0237 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 148.34 B | ||||
| Shares Outstanding | 1.26 B | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 82.92 % | ||||
| Number Of Shares Shorted | 21.39 M | ||||
| Price To Earning | 42.99 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CVS Stock Analysis
When running CVS Health's price analysis, check to measure CVS Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CVS Health is operating at the current time. Most of CVS Health's value examination focuses on studying past and present price action to predict the probability of CVS Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CVS Health's price. Additionally, you may evaluate how the addition of CVS Health to your portfolios can decrease your overall portfolio volatility.